Defining the Impact of Immunotherapy for Merkel Cell Carcinoma

Defining the Impact of Immunotherapy for Merkel Cell Carcinoma is organized by PRIME Oncology and will be held during Oct 17, 2017 - Oct 17, 2018.

The target audience for this medical event is specifically designed to meet the needs of healthcare providers involved in the therapeutic management of patients with Merkel cell carcinoma, including oncologists, dermatologists, surgeons, nurses, and researchers.

Topics :
• Brief overview of MCC
• Clinical presentation, including diagnostic and prognostic tools
• MCPyV role in treatment selection
• Current and emerging uses of checkpoint inhibitors for MCC

This Expert Review features internationally-renowned thought leaders discussing the latest data regarding the management of advanced Merkel cell carcinoma (MCC), including diagnostic and prognostic tools, the role of Merkel cell polyomavirus (MCPyV), and the current and emerging uses of checkpoint inhibitors for the treatment of MCC. This program also features a companion downloadable slide deck that includes key information covered in the discussion.

Conference Objectives are :
Upon completion of this educational activity, participants should be able to:
• Describe MCC and currently available diagnostic and prognostic tools
• Evaluate the role of MCPyV in guiding treatment selection for patients with MCC
• Explain ongoing clinical trials of PD-1/PD-L1 inhibitors in comparison with already established treatment options for patients with MCC

Additional details will be posted as soon as they are available.